Chromosome alterations and E-cadherin gene mutations in human lobular breast cancer by Huiping, C et al.
Loss of heterozygosity (LOH) has been studied at many chromo-
some regions in sporadic breast cancers and at least 15 different
chromosome arms have shown frequent LOH (Ingvarsson, 1999).
LOH at 16q is one of the most frequently occurring genetic events
in sporadic breast cancer (~67% of the informative cases),
indicating the presence of one or more tumour suppressor genes
at 16q (Tsuda et al, 1994; Skirnisdottir et al, 1995).
The E-cadherin gene is one of the candidate tumour suppressor
genes at 16q22.1, which is one of the smallest deletion regions at
16q (Cleton-Jansen et al, 1994). E-cadherin is expressed on the
cell surface in most epithelial tissues (Takeichi, 1990). The trans-
membrane molecule E-cadherin is considered to be one of the key
molecules for the formation of the intercellular junctional complex
and for the establishment of cell polarization (Gumbiner et al,
1988). The cytoplasmic tail of E-cadherin is linked via catenins to
the actin cytoskeleton (Cowin, 1994), whereas the extracellular
domain is involved in a molecular zipper mediating cell–cell adhe-
sion (Shapiro et al, 1995). E-cadherin showed an important inva-
sion suppressor activity in vitro (Frixen et al, 1991). Reduced
E-cadherin expression is associated with invasiveness in breast
cancer (Siitonen et al, 1996). Activation of E-cadherin can cause
growth retardation of tumour cells (Navarro et al, 1991; St Croix et
al, 1998). Mutations of the gene E-cadherin have been reported so
far in gastric carcinomas (Becker et al, 1993, 1994), gastric carci-
noma cell lines (Oda et al, 1994), cancers of the endometrium and
ovarium (Risinger et al, 1994), breast cancer cell lines (Hiraguri et
al, 1998) and lobular breast cancers (Kanai et al, 1994; Berx et al,
1995a, 1996). Furthermore, germline mutations in the E-cadherin
gene have been described in familial gastric cancer (Gayther et al,
1998; Guilford et al, 1998). These results strongly suggest that the
E-cadherin gene is a tumour suppressor gene.
By screening four exons (5, 6, 7 and 8) of the E-cadherin gene,
Kanai et al (1994) found that two (10%) of 20 lobular breast carci-
nomas showed point mutations. Berx et al (1996) reported 27 E-
cadherin mutations detected from a majority of 16 exons of
E-cadherin gene in a series of 48 lobular breast carcinomas. These
mutations were obviously scattered over the whole E-cadherin
gene, particularly in the exons encoding the extracellular domain
(Kanai et al, 1994; Berx et al, 1996). Interestingly, no mutations
were identified in 50 breast cancers of other histological subtypes
by Berx et al (1996).
In order to study the difference of genetic alterations in lobular and
ductal types of breast tumours we analysed LOH at 1p, 3p, 6q, 7q, 9p,
11q, 13q, 16q, 17q, 18q and 20q. We also investigated the association
between LOH at 16q and lobular histological type in order to under-
stand the involvement of 16q in the aetiology of lobular breast carci-
nomas. Furthermore, we screened a set of lobular breast tumours in
an attempt to find new E-cadherin mutations.
MATERIALS AND METHODS
Patients and tumour material
All 40 patients were diagnosed histologically as lobular breast
cancers at Department of Pathology of the University Hospital of
Iceland. Primary breast carcinoma tissue was obtained on the day
of surgery. Blood samples from the patients were collected in
EDTA and if not processed immediately the tumour tissue and
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Correspondence to:S Ingvarssonblood were quick frozen at –80°C. All relevant information about
the tumours, e.g. size, node status, receptor status (oestrogen
receptor (ER) and progesterone receptor (PR)), ploidy and S phase
fraction, was recorded by the same department. In this study 204
invasive ductal breast tumours were used as controls for LOH
analysis (Huiping et al, 1998).
DNA isolation
Salting out procedure (Miller et al, 1988) and phenol extraction
methods were used to obtain DNA from whole blood and tumour
samples respectively.
LOH determination
Microsatellite markers used for LOH analysis of chromosome 1p
were: D1S233, D1S496, D1S209, D1S488, and D1S435. The
microsatellite markers used for chromosome 3p were: D3S1211,
D3S1029, D3S1217, D3S1210 and D3S1101. The markers used
for 6q were: D6S262, D6S292, D6S409, D6S290 and D6S305.
The markers used for 7q were: D7S518, D7S515, D7S523,
D7S471 and D7S500. The markers used for 9p were: D9S156,
D9S157, INFA, D9S171 and D9S104. The markers used for 11q
were: D11S907, INT-2, D11S35, D11S4206, D11S925 and
D11S921. The markers used for 13q were: D13S260, D13S171,
D13S267, D13S219 and D13S263. The markers used for 16q
were: D16S503, D16S496, D16S421, D16S545 and D16S512 for
the 16q21–22.1 region containing the E-cadherin gene (Genome
Database). The markers used for 17p were: D17S945, D17S921,
D17S953, D17S925, D17S798 and D17S933. The markers used
for 17q were: D17S800, D17S855, D17S1322, D17S579 and
D17S784. The markers used for 18q were: D18S67, D18S474,
D18S51, D18S70 and D18S61. The markers used for 20q were:
D20S199, D20S118, D20S191, D20S119 and D20S196. The poly-
merase chain reaction (PCR) products were separated in an acryl-
amide sequencing gel and transferred to a positively charged nylon
membrane, Hybond-N+ (Amersham, Aylesbury, UK) and baked
for at least 2 h at 80°C. The non-radioactive detection method used
to visualize the PCR products has been described previously
(Vignal et al, 1993). Autoradiograms were inspected visually by at
least two reviewers, comparing the intensity of alleles from normal
and tumour DNA. The absence or a significant decrease of one
allele in the tumour compared to the normal reference sample was
considered as LOH.
PCR–SSCP analysis
All 16 exons of E-cadherin gene were screened for inactivation
mutations with a PCR–SSCP (single-strand conformation poly-
morphism) analysis on genomic DNA templates. The primers used
in the SSCP analysis were described in Berx et al (1995a) and
ordered from Pharmacia Biotech. Genomic DNA was used at
30 ng per 25 ml reaction mixture containing 5 pmol of the forward
and reverse primers, 2.5 nmol of each dNTP, 0.5 units of
DynaZyme polymerase. The samples were amplified in 35 cycles
composed of 30 s of denaturation at 95°C, 60 s of annealing at
55–70°C, and finally 60 s of extension at 72°C. A hot start was
used by adding the enzyme during the first cycle at about 72°C,
after a preincubation time of 5 min at 94°C. A 4 ml aliquot of PCR
products was mixed with 7 ml of formamide dye (95% formamide,
0.05% bromophenol blue and 0.05% xylene cyanol), denatured at
94°C for 10 min and snapcooled on ice. Aliquots of 2 ml were
analysed simultaneously on two non-denaturing polyacrylamide
gels (5% acrylamide with 2% cross-linking), either containing 5%
glycerol or lacking glycerol. Electrophoresis was performed in
1  ´ TBE on vertical gels (390 ´ 330 ´ 0.4 mm) at 6w overnight or
for 6 h at room temperature. The PCR products were visualized as
the microsatellite markers.
Sequencing of PCR products
Samples with abnormal mobility bands were amplified again for 35
cycles as described above. A 5 ml aliquot of the PCR product was
then incubated with 10 U exonuclease I and 2 U shrimp alkaline
phosphatase to remove excess of primers and dNTPs (US70995,
Amersham). Sequences of both strands were determined by thermo
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Figure 1 LOH in matched normal (N) and tumour (T) tissues from five lobular breast cancer patients with E-cadherin gene mutations. Case numbers are
shown at the top. Symbols at the bottom indicate the markers used. LOH in tumours is indicated by arrowssequenase DNA polymerase (Thermo Sequenase Radiolabeled
Terminator Cycle Sequencing Kit, Amersham) using either one of
the original PCR primers.
Immunohistochemical staining
Immunohistochemistry was performed on 5-mm sections from
paraffin-embedded tumour tissue blocks with monoclonal anti-
body HECD-1 (Zymed Laboratories, South San Francisco, CA,
USA) using the antigen retrieval protocol described by Hazelbag
et al (1995).
Statistical analysis
A c2 test was used to assess the relationship between LOH in lobular
tumours and LOH in ductal tumours at 1p, 3p, 6q, 7q, 9p, 11q,
13q, 16q, 17q, 18q and 20q. We also analysed the association
of LOH at different chromosome regions with the categorized prog-
nostic variables, LOH at other chromosome regions and E-cadherin
gene mutations by c2 test and Fisher’s exact test.
RESULTS
LOH analysis
LOH by the use of polymorphic microsatellite markers at chromo-
somes 1p, 3p, 6q, 7q, 9p, 11q, 13q, 16q, 17p, 17q, 18q and 20q in
40 lobular tumours was analysed (Figure 1). LOH for these chro-
mosome regions ranged from 17% to 100% (Tables 1 and 2). The
highest percentage of LOH was detected at the 16q21–q22.1
region where all examined cases (31/31) were positive. Table 2
shows the c2 analysis comparing LOH in lobular tumours with
LOH in ductal tumours investigated in our laboratory at the
different chromosome regions. There was a significant association
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Table 1LOH at different chromosome regions and immunohistochemical staining (IHCS) of E-cadherin in lobular breast tumours
Tumour 1p 3p 6q 7q 9p 11q 13q 16q 17p 17q 18q 20q E-cad
sample IHCS
402 ND + ND ND ND ND ND + ND ND ND ND ND
676 + – – – – – – + ND ND ND – –
743 – – – – + + – + ND + – + ND
745 – – – – – – – + ND ND ND – ND
806* ND ND ND ND ND ND ND + ND ND ND ND –
811 – – – + – + + + – ND – – ND
856 – – – – – – – + ND + ND – +
897 + + – – – + – + – + + + ND
908 + + + – – – – + ND ND ND – ND
936* + – – + + + + + + – + + (+)
986* – – – – – + + + ND – ND – (+)
1032 – – ND – ND – – + ND ND ND ND (+)
1036 – – – + – – – + – – – – ND
1061 – – + – – + – + ND – ND + –
1118 – – + – – – + + ND ND ND + –
1225 – ND – – – – – + – – + + (+)
1258 – – – – – – + + – – – + –
1301 – – + – – + + + – + – – –
1318* – – – + – + + + – – + – –
1327 – – – + – – + + – – – – –
1338 + – – + – – + + + + – + –
1341 – – ND + ND + ND + ND ND ND ND –
1367 ND ND ND ND ND ND ND + ND ND ND ND ND
1371 ND ND ND ND ND ND ND + ND ND ND ND (+)
1475 – – – + – + – ND + – + – (+)
1478 ND ND ND ND ND ND ND + ND ND ND ND –
1483 + – – – – – – + + – – – –
1499 ND ND ND ND ND ND ND ND ND ND ND ND –
1514 – – – – – – – + – – – – +
1515* + + – – – – – + – – – – –
1518 – + + + – + + + + – – + –
1520* ND ND ND ND ND ND ND ND ND ND ND ND –
1524 + + – + + – – ND – ND – – –
1534 + – + – – – – ND + + ND + –
1545 – – – – + – – ND – – – – –
1546 ND ND ND ND ND ND ND ND ND ND ND ND –
1548 + – – – + – – + – + – – –
1549 + – + + – + – ND – + – – –
1575 – – + + – – – ND – + – + ND
1583 – + – – – – – + – + + – –
Useful 11 7 8 12 5 12 10 31 6 10 6 11 29
Total 32 32 30 32 30 32 31 31 22 24 22 30 31
% 34 22 27 38 17 38 32 100 27 42 27 37 94
+, positive LOH or staining; –, negative LOH or staining; (+), weak staining; *, somatic mutation in the E-cadherin gene; ND, not determinedbetween lobular tumours and LOH at 16q (99.9% confidence
interval). There was also a significant association between ductal
tumours and LOH at 1p, 3p, 9p, 11q, 13q and 18q (Table 2). By
comparing all investigated chromosome regions in lobular breast
tumours, a significant association was detected between LOH at
13q and LOH at 7q (P = 0.049) and between LOH at 13q and LOH
at 11q (P = 0.049).
Mutational analysis of 40 lobular breast cancers by
PCR–SSCP
We studied a set of breast cancers from 40 patients for occurrence of
E-cadherin mutations. Mobility shifts were found in the amplicons
1, 2, 3, 4–5, 10, 13, 14 and 16 (Table 3). Tumours with mutation in
the E-cadherin gene, 936, 986, 1318 and 1515, show LOH at several
chromosomes in addition to chromosome 16q: chromosome 1p,
7q, 9p, 11q, 13q, 17p, 18q and 20q; chromosome 11q and
13q; chromosome 7q, 11q, 13q and 18q; and chromosome
1p and 3p respectively (Table 1).
DNA sequence analysis
By direct sequence analysis of the PCR products, five truncation
mutations were identified among the 40 lobular tumours (Figure 2
and Table 3). Three frameshift insertions and two frameshift
deletions were found, all resulting in premature downstream stop
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Table 2 Chi-square analysis comparing loss of heterozygosity (LOH) at different chromosome regions of tumour DNA to histological types
Chromosome Histological LOH/total % P
region type
1 p Lobular 11/32 34%
Ductal 111/194 57% 0.02c
3 p Lobular 7/32 22%
Ductal 48/96 50% 0.0054b
6 q Lobular 8/30 27%
Ductal 50/112 45% 0.08
7 q Lobular 12/32 38%
Ductal 54/180 30% 0.40
9 p Lobular 5/30 17%
Ductal 60/134 45% 0.0044b
11 q Lobular 12/32 38%
Ductal 62/107 58% 0.04c
13 q Lobular 10/31 32%
Ductal 88/146 60% 0.0044b
16 q Lobular 31/31 100%
Ductal 57/78 73% <0.001a
17 q Lobular 10/24 42%
Ductal 28/46 61% 0.13
18 q Lobular 6/22 27%
Ductal 123/192 64% <0.001a
20 q Lobular 11/30 37%
Ductal 39/117 33% 0.73
a99.9% confidence interval. b99% confidence interval. c95% confidence interval.
Exon 2 (986)–cd 45 insC Exon 10 (806)–cd 510 del 5 Exon 13 (936)–2165–1G      A
Normal Tumour
Frameshift insertion Frameshift deletion Splice site mutation
Normal Normal Tumour Tumour
GATC GATC GATC GATC GATC GATC
Figure 2 Three examples of sequence analysis of abnormally shifted PCR–SSCP bands, yielding three different mutation types as indicated at the bottom.
The arrows indicate the following sequence changes: (A) one basepair insertion cd 45 ins C; (B) five basepair deletion cd 510 del cccag; (C) splice site mutation
2165–1 G®A. The sample numbers are in parenthesescodons (Table 3). Most of the insertions and deletions were rather
small, causing 1-bp to 5-bp changes. Only one larger deletion of
22 bp was identified. We also identified one putative splice site
mutation for exon 13 (Figure 2 and Table 3). In the mutated splice
acceptor sequence of exon 13, GT was converted by a single base
substitution to AT (Figure 2 and Table 3). All of the six mutations
were found only once and have not been previously reported.
Sequencing of DNA for blood from all six patients with mutations
in breast tumours indicates that the mutations are not germline, but
tumour-specific.
Besides the six mutations, we also identified nine different poly-
morphisms of which four have been described before (Risinger et
al, 1994; Berx et al, 1995a, 1996). Besides the frequent polymor-
phism in the intron 4, a previously unreported but frequent poly-
morphism (four out of 38) was identified in the intron 15 sequence
from amplicon 16. Polymorphisms are shown in Table 3.
Immunohistochemistry
Of the 31 lobular tumours analysed by immunohistochemistry, 29
(94%) showed no or reduced membrane-associated E-cadherin
staining with monoclonal antibody HECD-1 and only two showed
a clear membrane-associated expression of E-cadherin (Figure 3
and Table 1). In particular, four samples 806, 986, 1318 and 1515
with truncation mutations plus LOH at 16q22.1 were negative or
showed reduced E-cadherin protein expression (Table 3 and Figure
3). All lobular breast tumours lack membrane staining, while two
of them show weak cytoplasmic staining.
Association analysis of the lobular breast tumours
We found an association between E-cadherin gene mutations and
LOH at 13q and 16q (P = 0.05). A significant association was also
found between LOH at 3p and high S phase, LOH at 9 p and low
ER and PR content, LOH at 17p and aneuploidy (P = 0.033, 0.011,
0.001, 0.014 respectively). A trend was detected between LOH at
1p and tumours larger than 2 cm (P = 0.052).
DISCUSSION
In this study, LOH at 16q22.1 was detected in all lobular breast
tumours examined. This is a higher rate than those reported in
previous studies (Tsuda et al, 1994; Skirnisdottir et al, 1995; Berx et
al, 1996) presumably due to difference in the set of markers used.
LOH at 16 q in lobular tumours was compared with LOH at 16 q in
ductal tumours using the same microsatellite markers. The detected
association suggests that the chromosome 16q22.1 region contains
one or more suppressor genes particularly relevant to lobular breast
carcinogenesis. LOH for the 16q22.1 region has been detected in
several carcinoma types besides breast cancer, also suggesting the
presence of tumour suppressor genes at this region (Tsuda et al,
1990; Bergerheim et al, 1991; Sato et al, 1991). We also compared
LOH at other chromosome regions in lobular and ductal breast
tumours and found a higher LOH at 1 p, 3 p, 9 p, 11 q, 13 q and 18
q in ductal tumours, indicating a difference in genetic alterations in
the two histological types of breast cancers.
The human E-cadherin gene has been mapped to chromosome
16q22.1 (Mansouri et al, 1988; Natt et al, 1989). Its expression was
reduced in several types of human carcinomas (Shimoyama et al,
1991; Bussemakers et al, 1992; Inoue et al, 1992; Umbas et al,
1992). Mutations of the E-cadherin gene have been identified in
human tumours and tumour cell lines (Becker et al, 1993, 1994;
Kanai et al, 1994; Oda et al, 1994; Risinger et al, 1994; Berx et al,
1995a, 1996). These observations in combination with LOH at
16q22.1 indicate that the E-cadherin gene is a tumour suppressor
gene. Our data reported here consolidate the evidence for E-
cadherin playing an important role as a typical tumour suppressor
in lobular breast carcinomas. Since no mutations in the E-cadherin
gene have been detected in tumours in the breast of the ductal histo-
logical type (Berx et al, 1996), this provides the clearest evidence of
molecular difference in the two main histological types of breast
carcinomas. Nonetheless, reduced expression of E-cadherin has
been found in both lobular and ductal breast cancers (Oka et al,
1993; Gamallo et al, 1996) and detection of chromosome 16q22.1
is the highest documental loss of a chromosome region in sporadic
breast cancers of both histological types (Skirnisdottir et al, 1995;
this study). Two explanations of this difference are possible, either:
(1) a gene other than the E-cadherin gene is the target of the
16q22.1 deletion in ductal compared to lobular carcinomas of
breast cancer; or (2) the progression of ductal carcinomas is more
sensitive to loss of one copy of the E-cadherin gene, and corre-
sponding reduction of expression, than lobular breast carcinomas,
where both copies need to be eliminated for further progression to
malignant invasive growth. The LOH detected in this study is prob-
ably due to loss of genetic material for chromosome 16q22.1 since
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Figure 3 (A) Case no. 1338. Normal duct with positive staining for
E-cadherin in non-neoplastic ductal cells and lobular carcinoma in situ within
the duct negative for E-cadherin. In the surrounding tissue infiltrating lobular
carcinoma cells are negative for E-cadherin. (B) Case no. 936. Infiltrating
lobular carcinoma cells showing mild diffuse cytoplasmic staining for
E-cadherinreduced expression of the E-cadherin is detected as well, but our
method in detecting LOH does not exclude a duplication of a locus
due to mitotic recombination.
Altogether, we examined 40 lobular breast tumours on the
genomic level for E-cadherin mutations. Besides polymorphisms,
six mutations were identified by our E-cadherin PCR/SSCP
analysis. None of the mutations described here have been reported
before. In agreement with the mutations reported by Berx et al
(1996), most of the mutations (5/6) were caused by frameshifts,
usually resulting in premature stop codons (Table 3). Although a
large series of lobular tumours was analysed, we could not identify
any non-sense mutation, in contrast with a previous report on five
non-sense mutations in a series of 48 lobular tumours (Berx et al,
1995a, 1996). Besides truncation mutations we also found a splice
site mutation, affecting the acceptor splice site and probably
causing skipping of exon 14 (Table 3). This particular tumour
shows a weak cytoplasmic E-cadherin staining. Becker et al (1993,
1994) have found frequent skipping of exon 8 or 9 in diffuse gastric
carcinomas. It is noteworthy that exon 14 is encoding the part of the
transmembrane domain necessary for binding membrane and the
part of the cytoplasmic domain necessary for binding
b-catenin and plakoglobin (g-catenin) (Aberle et al, 1994).
E-cadherins are linked to the actin cytoskeleton by the introduction
of catenins, resulting in tight cell–cell adhesion (Cowin, 1994). The
aberrant transmembrane domain and cytoplasmic domain can
affect the cell–cell adhesion. Interestingly, the six novel mutations
were scattered over all five E-cadherin domains, including the
signal and precursor sequences (Table 3).
The various truncated E-cadherin peptides are likely to be
secreted and to have some residual function which could interfere
with proper cell–cell adhesion in the peritumoral tissues (Berx et
al, 1996). Furthermore, these fragments and even small deca-
peptides containing the HAV sequence, known to be involved in
homophilic recognition, can disturb proper cell–cell adhesion
(Blaschuk et al, 1990). Therefore, it may be interesting to investi-
gate the treatment of lobular tumours with related antibodies that
can be synthesized in vitro according to the genes with truncation
or splice site mutations.
For all informative lobular breast tumours, which we found to
lack membrane E-cadherin expression, we identified both LOH of
16q22.1 harbouring the E-cadherin locus and mutations in the
remaining allele, in accordance with the classical two-hit theory of
Knudson for tumour suppressor genes (Knudson, 1985). This
supports the results reported by Berx et al (1995a, 1996). This is
also supported by an association between E-cadherin gene muta-
tions and LOH at 16q. Presumably, LOH at 13q could enhance the
lobular tumour growth triggered by E-cadherin gene mutation and
LOH at 16q because we also found an association between E-
cadherin gene mutations and LOH at 13q. Transfection of MET/6
mouse mammary carcinoma cells, which lack E-cadherin, with an
exogenous E-cadherin expression vector, resulted in tighter adhe-
sion of multicellular spheroids and a reduced proliferative fraction
in three-dimensional culture (St Croix et al, 1998). Exposure to E-
cadherin-neutralizing antibodies in three-dimensional culture
simultaneously prevented adhesion and stimulated proliferation of
E-cadherin transfectants as well as a panel of human colon, breast
and lung carcinoma cell lines that express functional E-cadherin
(St Croix et al, 1998). From these, it can be concluded that
E-cadherin, classically described as an invasion suppressor, is also
a major growth suppressor.
We identified loss of or reduced E-cadherin expression in 29 out
of 31 lobular breast tumours, in accordance with earlier studies
(Gamallo et al, 1993; Rasbridge et al, 1993). However, only six
out of 29 lobular tumours lacking E-cadherin expression showed
detectable E-cadherin mutations, suggesting that loss of one copy
of the E-cadherin gene may affect the expression of the remaining
allele. This is lower frequency of mutations than reported by Berx
et al (1995a, 1996). The number of mutations reported here is
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Table 3 Summary of E-cadherin gene mutations and polymorphisms detected in a series of 40 lobular breast tumours
Amplicon Tumour Mutation Mutation Nucleotide change LOHc E-cad
No.a sample siteb IHCd
1 1318 cd 8 frameshift del 22 (stop at cd 48)e yes –
2 986 cd 45 frameshift ins C (stop at cd 58) yes (+)
2 1520 cd 51 frameshift ins G (stop at cd 58) NT –
10 806 cd 510 frameshift del 5 (stop at cd 534)f yes –
13 936 intron 13 splice site 2165–1 G®A yes (+)
14 1515 cd 726 frameshift ins T (stop at cd 747) yes –
Amplicon Site Polymorphism Observed frequency
3 intron 2 tttctccc®tttctgccc 2/38
3 cd 115 ACG(Thr)®ACA(Thr) 1/38g
4–5 intron 4 gaaac®gaaag 6/38h
13 cd 692 GCC(Ala)®GCT(Ala) 3/38i
14 cd 751 AAC(Asn)®AAT(Asn) 1/38j
14 cd 764 GAC(Asp)®GAT(Asp) 1/38
16 cd 878 GGC(Gly)®GGT(Gly) 1/38
16 intron 15 ttgag®tttag 4/38
16 intron 15 ttctt®ttgtt 1/38
aAmplicons contain besides exons also flanking intronic sequences and in the case of amplicon 4–5 the whole intron 4 is present, too. bcd, codon. cLOH, loss of
heterozygosity at 16q22.1. dE-cad IHC: E-cadherin specific immunohistochemistry. NT, no tumour material available for LOH analysis. –, no cell surface
associated staining. (+), weak or cytoplasmic staining, +, normal staining. e22 bp deletion at codon 8 of exon 1: 5¢-ctctcggcgctgctgctgctgc-3¢. f5 bp deletion at
codon 510 of exon 10: 5¢-cccag-3¢. g–jThese polymorphisms were also reported by Berx et al. (1995a). iThis polymorphism was also reported by Risinger et al
(1994). jThis polymorphism was reported previously by Risinger et al (1994) and by Becker et al (1994).probably underestimated, either due to low efficiency of SSCP or
that some tumours were lacking data from all exons. In addition to
this the reduced expression may be due to transcriptional defects
(Ji et al, 1997). Synthesis of mRNA could be affected by mutations
in the promoter region, or in intron located regulatory sequences,
whereas stability of mRNA could be affected by mutations in the
untranslated regions (Berx et al, 1996). CpG-island overspanning
intron 1 of the E-cadherin gene (Berx et al, 1995b) was found to be
densely methylated in breast cancer cell lines, and this correlated
with loss of E-cadherin expression (Graff et al, 1995). Moreover,
p53 protein accumulation and c-erbB-2 protein overexpression
may play a role in regulation of E-cadherin expression (Bukholm
et al, 1997).
Catenins link E-cadherin molecules to the actin cytoskeleton
and lay a solid foundation for the tight cell–cell adhesion (Cowin,
1994). Therefore, loss of or reduced catenin expression also inter-
feres with cell–cell adhesion. Simultaneous loss of E-cadherins
and catenins have been detected in invasive lobular breast cancer
and lobular carcinoma in situ (De Leeuw et al, 1997). Thus, it may
be important to detect mutations in the catenin genes in lobular
breast tumours or other epithelial carcinomas.
A number of studies have revealed that chromosome deletions
in breast cancers may occur in preferred combinations with respect
to growth advantage, e.g. 1p and 3p (Ragnarsson et al, 1996), 7q
and 1p (Kristjansson et al, 1997), 3p and 6q (Bragadottir et al,
1995), 9p and 6q (Eiriksdottir et al, 1995), 13q and 17p (Anderson
et al, 1992), 11p and 17p (Takita et al, 1992), 18q and 1p, 7q, 9p,
13q and 17q (Huiping et al, 1998). In order to determine whether
there are specific combinations of chromosome deletions in
lobular breast tumours, we compared LOH at different chromo-
some regions and found a weak association between LOH at 13q
and LOH at 7q and 11q.
LOH at different chromosome regions was compared with
various clinicopathological variables of the lobular breast carci-
nomas. A significant association was found between LOH at 9p
and low ER and low PR. This suggests that LOH at 9p could be
involved in the loss of ER and PR content. A weak association was
found between LOH at 3p and high S phase fractions and a trend
between LOH at 1p and tumour larger than 2 cm. This suggests
that genes at 3p and 1p could possibly have a restraining effect on
the rate of cell proliferation, and the loss of them would lead to a
rapid growth. We also found a weak association between LOH at
17p and aneuploidy, indicating that LOH at 17p could be associ-
ated with an unstable genome.
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